Section

Markets

Capital, M&A, and what biotech is worth this week.

Editorial cross-section of a KCNT1 potassium channel with a small-molecule plug, beside a sparse U.S. map implying 2,500 patients

Markets 10 Aug 2026

What $820 million for a Phase 1b/2 KCNT1 inhibitor says about rare-epilepsy assets — and about Jazz

Jazz agreed on 10 August to buy Actio Biosciences for $820 million cash plus $500 million in milestones, spinning out everything that is not ABS-1230, to bolt a precision ion-channel drug onto Epidiolex.

Two injector pens and an oral blister pack on a cool grey field beside a simple two-bar chart of Lilly revenue up and Novo guidance still negative

Markets 6 Aug 2026

What Lilly’s 48% quarter and Novo’s raised-but-still-shrinking outlook mean for the incretin duopoly

Two earnings prints in 48 hours showed the obesity market splitting: Lilly raised the ceiling; Novo raised guidance into a decline.